The additional diagnostic yield of long-read sequencing in undiagnosed rare diseases
Genome Research · 2025-04 · 35 (4) · 559-571
DOI: 10.1101/gr.279970.124 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genome Research, online erschienen am 03.02.2025. Verfasst von Giulia F Del Gobbo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada K1H 5B2. Hauptthemen laut MEDLINE: Rare Diseases, High-Throughput Nucleotide Sequencing, Sequence Analysis, DNA, Undiagnosed Diseases. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Care4Rare Canada Consortium, Genome Canada and the Ontario Genomics Institute, Canadian Institutes of Health Research, Ontario Research Fund, Genome Alberta, Genome British Columbia, Génome Québec, and Children's Hospital of Eastern Ontar….
Abstract (Originalsprache)
Long-read sequencing (LRS) is a promising technology positioned to study the significant proportion of rare diseases (RDs) that remain undiagnosed as it addresses many of the limitations of short-read sequencing, detecting and clarifying additional disease-associated variants that may be missed by the current standard diagnostic workflow for RDs. Some key areas where additional diagnostic yields may be realized include: (1) detection and resolution of structural variants (SVs); (2) detection and characterization of tandem repeat expansions; (3) coverage of regions of high sequence similarity; (4) variant phasing; (5) the use of de novo genome assemblies for reference-based or graph genome variant detection; and (6) epigenetic and transcriptomic evaluations. Examples from over 50 studies support that the main areas of added diagnostic yield currently lie in SV detection and characterization, repeat expansion assessment, and phasing (with or without DNA methylation information). Several emerging studies applying LRS in cohorts of undiagnosed RDs also demonstrate that LRS can boost diagnostic yields following negative standard-of-care clinical testing and provide an added yield of 7%–17% following negative short-read genome sequencing. With this evidence of improved diagnostic yield, we discuss the incorporation of LRS into the diagnostic care pathway for undiagnosed RDs, including current challenges and considerations, with the ultimate goal of ending the diagnostic odyssey for countless individuals with RDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada K1H 5B2.
- Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada K1H 5B2; kboycott@cheo.on.ca.
- Department of Genetics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada K1H 8L1.
ORCID-Profile: Giulia F Del Gobbo, Kym M Boycott
Förderung
- Care4Rare Canada Consortium
- Genome Canada and the Ontario Genomics Institute
- Canadian Institutes of Health Research, Ontario Research Fund, Genome Alberta, Genome British Columbia, Génome Québec, and Children's Hospital of Eastern Ontar…
- CIHR
- CIHR Foundation
- Canada Research Chair in Rare Disease Precision Health
Zitieren
APA
Del Gobbo, G. F., & Boycott, K. M. (2025). The additional diagnostic yield of long-read sequencing in undiagnosed rare diseases. Genome Research, 35(4), 559-571. https://doi.org/10.1101/gr.279970.124
Vancouver
Del Gobbo GF, Boycott KM. The additional diagnostic yield of long-read sequencing in undiagnosed rare diseases. Genome Research. 2025;35(4):559-571. doi:10.1101/gr.279970.124
BibTeX
@article{DelGobbo2025,
author = {Del Gobbo, Giulia F and Boycott, Kym M},
title = {The additional diagnostic yield of long-read sequencing in undiagnosed rare diseases},
journal = {Genome Research},
year = {2025},
volume = {35},
number = {4},
pages = {559--571},
doi = {10.1101/gr.279970.124}
}
EUVIMED